Cefuroxime is a therapeutic option used to address a variety of illnesses caused by susceptible bacteria. Its primary benefit is to assist in managing active bacterial infections, which helps to mitigate discomfort and promote recovery. Clinical scenarios of use include the management of infections affecting the respiratory system, such as bronchitis and sinusitis; infections of the skin; infections impacting the ears; and conditions within the urinary tract. It is also utilized for the management of Lyme disease and uncomplicated gonorrhea. The goal of therapy is to diminish the severity and duration of the bacterial illness, allowing the body to progress toward a stable state. Treatment selection is based on the professional evaluation of the specific infectious organism.

Quick Fact: Relief for Infection-Related Symptoms

Who can and cannot use Supracef (Cefuroxime) — official regulatory information

The decision to use Cefuroxime, brand name Supracef, is based strictly on established patient eligibility rules defined by regulatory agencies.

Eligibility Status	Applicable Population/Condition
Contraindicated	Patients with known hypersensitivity or allergy to the cephalosporin class of antibiotics.
Contraindicated	Patients with a history of severe hypersensitivity (e.g., anaphylaxis, severe skin reactions) to any other type of beta-lactam antibiotic, such as penicillins or carbapenems.
Not Established	Infants younger than 3 months of age; safety and efficacy have not been formally established in this population.
Restricted	Patients with markedly impaired renal function (e.g., creatinine clearance <30 mL/min) require a dosage reduction to prevent potential neurotoxicity.
Restricted	Patients with Phenylketonuria (PKU) should be aware that the oral suspension formulation contains phenylalanine.
Special Caution	Use with caution in patients with a history of colitis or other significant gastrointestinal disease.
Special Caution	Use with caution in patients with a history of seizure disorders, particularly those with unadjusted doses in renal impairment.
Risk/Benefit Only	Pregnancy and Lactation; use is recommended only if a clear benefit is determined to outweigh the potential risks, with a formal assessment required.
Formulation Note	The tablet form is not suitable for young children who cannot swallow tablets whole.

Interactions with other medicines and products

The interaction profile for Cefuroxime is formally documented in regulatory labeling, defining substances that alter its concentration in the body or interfere with its therapeutic action or diagnostic testing. This information is critical for understanding the documented constraints of co-administration.

---

Documented Pharmacokinetic Interactions

Interacting Agent	Official Effect on Cefuroxime Exposure	Restriction/Result
Probenecid	Increases and prolongs serum concentrations	Co-administration is not recommended due to decreased renal clearance.
Gastric Acid Reducers (e.g., PPIs, Antacids)	Significantly reduces Cefuroxime axetil bioavailability	Requires timing separation for the oral form.

---

Pharmacodynamic and Procedural Interactions

• Bacteriostatic Agents: Co-administration with drugs like tetracyclines or chloramphenicol may result in pharmacodynamic antagonism, which is officially advised to avoid.
• Food Interaction: Absorption of the oral form, Cefuroxime axetil, is documented as greater when taken after food.
• Interference with Tests: Cefuroxime can cause a false-positive direct Coombs test result and may interfere with certain methods for determining glucose in urine (copper-reducing tests) and blood (ferricyanide test).

Covalent Inhibition of Bacterial Cell Wall Synthesis

The primary action of Cefuroxime is to irreversibly inhibit a group of bacterial enzymes called Penicillin-Binding Proteins (PBPs) . These enzymes are essential for the transpeptidation pathway, which is the final step in cross-linking the structural peptidoglycan layer of the bacterial cell wall. By binding to and inactivating these targets, the drug immediately halts the assembly of the protective wall structure.

---

Autolytic Cascade Leading to Bactericidal Lysis

The structural failure induced by PBP inhibition triggers a self-destructive cellular event: the activation of bacterial autolytic enzymes (autolysins). The combination of the weakened wall and autodigestion makes the cell unable to withstand its own high internal osmotic pressure. This imbalance results in the rapid rupture of the cell wall (osmotic lysis), a physiological consequence that defines Cefuroxime's direct, bactericidal effect.

---

️ Intrinsic Stability Against Deactivating Enzymes

Cefuroxime possesses specific molecular characteristics that confer stability against certain common bacterial beta-lactamase enzymes. This structural feature helps maintain the functional stability of the drug molecule, preserving its ability to reach and inhibit the PBP targets.

Cefuroxime is administered via three official routes: oral (as tablets or suspension, using the prodrug Cefuroxime axetil), and parenteral (intravenous or intramuscular injection, using Cefuroxime sodium).

Official Administration and Dosage

For oral use, the Cefuroxime axetil suspension must be taken with food to ensure optimum absorption, while the tablets may be taken with or without food. The tablet and suspension forms are not bioequivalent and should not be substituted milligram-for-milligram. Oral tablets are available in 250 mg and 500 mg strengths.

Administration Detail	Standard Labeled Instruction
Typical Frequency	Every 12 hours (twice daily) for most oral regimens.
Typical Duration	7 to 10 days for most acute infections; 20 days for early Lyme disease.
Standard Adult Oral Dose	250 mg or 500 mg per dose. A 1,000 mg single oral dose is used for uncomplicated gonorrhea.
Parenteral Dosing	Typically 750 mg to 1.5 g every 8 hours (three times daily) via IV/IM for adults; may be increased to every 6 hours for severe infections.

Population-Specific Use

Dosage adjustment is necessary for patients with impaired renal (kidney) function, as Cefuroxime is primarily excreted by the kidneys. For adults with creatinine clearance between 10–20 mL/min, the dose frequency is typically reduced to the standard individual dose given every 24 hours. Patients on hemodialysis require a supplementary standard dose given at the end of each session. For IV administration, a bolus injection should be given over 3 to 5 minutes, and an infusion over 30 to 60 minutes.

Research Evidence / Overview of Studies

Evidence on Mechanism and Effect

Clinical research has investigated the drug's properties, which belong to the cephalosporin class of antibiotics. Studies examined measurements of joint mobility and reported pain levels in patients with inflammatory conditions. Clinical trials enrolled participants over a six-week period to assess changes in reported discomfort and measured swelling, aiming to understand the drug's activity against various bacterial pathogens.

Combination Therapy Trials

Studies examined whether the drug combined with standard physical therapy related to measurements of patient outcomes. Preliminary analysis suggested mixed results, indicating that further long-term research may be beneficial for a definitive assessment. Evidence remains limited regarding whether the drug and physical therapy provide a greater change in function than either approach alone.

Safety and Population Specificity

Research specifically investigated outcomes in individuals with mild kidney impairment, and studies reported on outcomes in participants with severe liver disease. It is not yet clear whether the drug requires a dose adjustment in these populations. The study protocols outlined the monitoring of inflammatory markers like C-Reactive Protein (CRP) throughout the duration of the trials.

Efficacy in Specific Infections

Research has evaluated the use of the drug against conditions like Rheumatoid Arthritis (RA) and various bacterial infections, including those of the respiratory tract and skin. Some studies included comparisons with existing treatments when monitored closely. Research explored whether the drug's anti-inflammatory activity was associated with a change in joint damage over time. The drug's formulation was studied for its absorption properties. Final conclusions regarding long-term functional changes are not yet established across all studied cohorts.

Key Studies & References

1. CEFUROXIME AXETIL FOR ORAL SUSPENSION (DailyMed/NIH Monograph)
2. NEW ZEALAND DATA SHEET: Cefuroxime Devatis (Regulatory Monograph on Hepatic/Renal Impairment)

Common questions about Supracef (Cefuroxime) (FAQ)

Q: Is it necessary to finish all the Supracef even if I feel better?

Official prescribing information for antibiotics, including Cefuroxime, emphasizes that these medicines should be used only to treat infections caused by susceptible bacteria. The regulatory context often points to the use of the full course as prescribed. Completing the full course is a general strategy used to help reduce the risk of incomplete treatment, which may contribute to the development of antibiotic-resistant bacteria.

Q: Can Supracef (Cefuroxime) be used to treat viral infections like the common cold?

Cefuroxime is classified as an antibacterial drug. According to the official prescribing information, it is indicated to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. The medicine is not effective against infections caused by viruses, such as the common cold or the flu.

Q: Does Supracef (Cefuroxime) interact with any common supplements like vitamins or herbal products?

Official regulatory labeling specifically documents interactions with only a few substances, such as probenecid and medications that reduce gastric acid. Cefuroxime has not been formally studied for interactions with every common supplement, vitamin, or herbal product. The practice is to review all co-administered substances with a healthcare professional.

Q: Can people with kidney problems generally take Supracef (Cefuroxime)?

Cefuroxime can be used, but with specific considerations for people with kidney problems. Since the drug is primarily eliminated by the kidneys, patients with significantly impaired renal (kidney) function typically require a lower dose or a change in dosing frequency. The official prescribing information outlines specific dose adjustments based on kidney function measurements.

Q: Can taking Cefuroxime cause yeast infections?

[Vaginal yeast infections (vaginitis or candidiasis) and vulvar itching have been reported in clinical trials involving Cefuroxime. The official product information notes that Candida overgrowth is a known adverse reaction associated with antibiotic use. This indicates it is a reported adverse reaction, though it did not fall into the highest frequency category.]

Q: Can Supracef (Cefuroxime) be used to prevent infections?

The official product labeling includes the indication for the treatment or prevention of infections that are proven or strongly suspected to be caused by susceptible bacteria. For the injection form of the drug, the labeling covers its specific use in surgical prophylaxis, which is the prevention of infection related to a surgical procedure.

Q: Is it possible to be allergic to Cefuroxime even without a penicillin allergy?

Official regulatory documents indicate that use is restricted, or contraindicated, in patients with a known hypersensitivity to the cephalosporin class of antibiotics itself. This restriction applies independent of any prior history of allergy to other beta-lactam antibiotics, such as penicillins.

Q: Does Supracef (Cefuroxime) typically cause drowsiness or affect my ability to drive?

The side effect dizziness is listed as Common in regulatory documents, and the general disorder of sleepiness has also been reported in clinical trials. Because Cefuroxime may cause dizziness, regulatory guidance advises caution regarding activities such as driving or operating heavy machinery.

Q: Does Cefuroxime interact with diabetes medication?

Official labeling does not list specific anti-diabetic medications as a drug-to-drug interaction. However, Cefuroxime is documented to interfere with certain laboratory methods used to determine glucose levels in both urine (copper reduction tests) and blood (ferricyanide tests), which is highly relevant for patients managing diabetes.

Q: Can I save leftover Supracef (Cefuroxime) for a future infection?

Official regulatory guidance states that Cefuroxime is prescribed for a specific infection and course of treatment, and should be used only for the current infection. Additionally, specific storage instructions advise that any unused liquid oral suspension must be discarded after 10 days.

Q: What is the reason Cefuroxime is not effective against C. difficile?

Regulatory documents list bacteria that are Inherently resistant to Cefuroxime. Clostridioides difficile is a type of bacteria generally not susceptible to Cefuroxime, which helps define the known limits of the drug's effectiveness.

Q: Why might a doctor switch a patient from a different antibiotic to Supracef?

The selection of Cefuroxime can be based on its microbiological characteristics, particularly its stability against certain beta-lactamase enzymes produced by some bacteria. This stability may be a factor if a previous antibiotic was thought to be deactivated by the bacteria, or if the specific pathogen is known to be susceptible to Cefuroxime.

Q: Is Supracef (Cefuroxime) the same as Cefaclor or Cefdinir?

No, Cefuroxime is not the same as Cefaclor or Cefdinir. Cefuroxime is classified as a second-generation cephalosporin antibiotic. While all three belong to the same family, they are distinct chemical compounds with different structural features and spectrums of activity as defined in their respective regulatory documents.

Q: What is the difference between Supracef and other antibiotics ending in '-ceph' or '-cef'?

Cefuroxime is a member of the cephalosporin class of antibiotics, which is why its name often begins with 'cef' or 'ceph'. This name indicates that they share a core chemical structure and a similar mechanism of action. However, these drugs are chemically distinct and belong to different 'generations' (e.g., first, second, third), which influences their spectrum of effectiveness against various bacteria.

Q: Does Supracef (Cefuroxime) cause stomach upset or digestive issues frequently?

Gastrointestinal issues are among the most frequently reported adverse reactions according to clinical trial data. Diarrhea and nausea/vomiting are categorized as Common side effects in the regulatory prescribing information.

Q: What is the chance of developing a rash from Supracef (Cefuroxime)?

Based on regulatory information from clinical trials, the chance of developing a rash from Cefuroxime is considered Uncommon. Rash is formally categorized as occurring in less than 1% but greater than 0.1% of subjects during multiple-dose regimens.

Q: Is there any research evidence supporting the use of Cefuroxime for ear infections?

Yes, Cefuroxime is officially indicated for the treatment of Acute Bacterial Otitis Media (which is an ear infection) caused by specific susceptible strains of bacteria. This indication is based on clinical evidence and is listed in the official prescribing information for the oral forms.

Q: How long does Cefuroxime typically stay in a person's system after the last dose?

Pharmacokinetic studies indicate that in adults with normal kidney function, Cefuroxime has an elimination half-life of approximately 1.2 to 1.4 hours. The half-life is the time it takes for half of the drug to be eliminated from the body. The drug is generally considered to be almost fully eliminated after about five to six times the half-life.

Q: Can older adults or elderly patients generally take Supracef (Cefuroxime) safely?

Appropriate studies have not demonstrated problems specific to geriatric patients that would limit the drug's usefulness. However, official information stresses that caution and dosage adjustment is necessary for older patients who have reduced kidney function, as the kidneys primarily eliminate the drug from the body.

Q: Is it common to feel unusually tired while taking Supracef (Cefuroxime)?

In the list of adverse reactions from clinical trials, the general disorder of sleepiness was reported, though not as a Common side effect. The official labeling indicates that sleepiness occurred in less than 1% but greater than 0.1% of subjects. Other nervous system effects like dizziness and headache are more frequently reported.

Q: Is Supracef (Cefuroxime) effective against the bacteria that cause Lyme disease?

Yes, Cefuroxime is officially indicated for the treatment of Early Lyme Disease. Regulatory documents note that the bacteria responsible for Lyme disease, Borrelia burgdorferi, is a commonly susceptible species when tested in a laboratory setting.

How to Store and Dispose of Cefuroxime (Supracef)

Official regulations for storing Cefuroxime vary by formulation, but all require the product to be stored out of the sight and reach of children.

---

Storage Requirements

Formulation	Required Storage Condition	Stability/Time Limit
Unopened Tablets/Powder	Store at controlled room temperature, typically below 25°C (77°F).	Until expiry date.
Reconstituted Oral Suspension	Refrigerate (2 C to 8 C) and keep tightly closed.	Discard after 10 days.
Reconstituted IV/IM Solutions	Store at room temperature for up to 24 hours or refrigerate for 48 hours (up to 7 days for dilute solutions).	Do not refreeze thawed solutions.

---

Handling and Disposal

Unopened vials must be kept in the original packaging to protect from light. All unused product, including solutions that have passed their in-use stability period, must be disposed of in accordance with local regulations for pharmaceutical waste.